Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer.
about
Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapyImage-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature.Development of nanoscale approaches for ovarian cancer therapeutics and diagnosticsConvergence of nanotechnology with radiation therapy-insights and implications for clinical translation.Positron emission tomography image-guided drug delivery: current status and future perspectives.MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.Neutron-activatable needles for radionuclide therapy of solid tumors.Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway.Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer.Imaging Gliomas with Nanoparticle-Labeled Stem Cells.Neutron-activatable radionuclide cancer therapy using graphene oxide nanoplatelets.Neutron-Activatable Nanoparticles for Intraperitoneal Radiation Therapy.In-Situ Formation of Holmium Oxide in Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron-Activatable Radiotherapeutics.
P2860
Q26746186-1DE7AF57-9BE8-45E2-BB92-E6A5D4DA3C47Q28066010-91DBB61D-9DF5-46C2-A92C-060CCF239608Q30394677-BA1633EA-151D-44D2-887B-03572541FC8BQ30421664-017E827A-2350-49CB-BDD0-46C54183F361Q34263669-38A3F2C5-BFE4-487B-B319-1E7CA746B883Q34446108-3833CB6A-5CC2-4A57-A4AC-6F5AE75EFDA7Q38154210-07F8CDCA-C664-4165-9B2D-02A2CC5FC423Q41654060-D3F4A870-BD8F-4EEA-B5B9-7AE8661B028EQ44874712-B18EADE1-B7F5-4D2C-AFF5-1C5A22D4AF50Q49335746-1DF53A56-6C50-4E6A-9703-6A627F04B11BQ51133864-E7BD9EF3-5661-4A36-875D-0F4E1E5AFE56Q52665037-D74DF7FF-496A-4330-8B22-11A1E4081D1AQ52765342-DC518457-13AE-4919-A5A1-1A5953FA36EFQ52915309-E96E0FD5-AFF5-4D1E-B2B3-64F026F6F496Q53723990-C7463CA8-FC9C-40F4-B4D6-16047933A1A9
P2860
Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@en
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@nl
type
label
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@en
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@nl
prefLabel
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@en
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@nl
P2093
P1476
Neutron-activatable holmium-co ...... utic agent for ovarian cancer.
@en
P2093
Anthony J Di Pasqua
James E Huckle
Jin-Ki Kim
Matthew Sadgrove
Michael Jay
Thanh Huyen Tran
Xiuling Lu
Younjee Chung
P304
P356
10.2967/JNUMED.112.106609
P407
P577
2012-10-25T00:00:00Z